Pipeline Overview

We have a robust drug development pipeline at various clinical and pre-clinical stages.

Note: 1 We own global rights to Plinabulin in all countries except China. In China, we own a 57.97% interest in our Chinese subsidiary, Dalian Wanchunbulin Pharmaceuticals Ltd. (“Wanchunbulin”), which owns a 100% interest in Plinabulin.

© 2020 BeyondSpring Inc. All rights reserved.